Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials.

@article{Boneschi2003EffectsOG,
  title={Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials.},
  author={Filippo Martinelli Boneschi and Marco Rovaris and Kenneth P. Johnson and Aaron Miller and Jerry S. Wolinsky and David Ladkani and Galia Shifroni and Giancarlo Comi and Massimo Filippi},
  journal={Multiple sclerosis},
  year={2003},
  volume={9 4},
  pages={349-55}
}
Three randomized, double-blind, placebo-controlled trials have shown that glatiramer acetate (GA) is effective in reducing relapse rate in patients with relapsing-remitting (RR) multiple sclerosis (MS). Using raw data pooled from 540 patients, we performed a meta-analysis of these three trials, to investigate whether the extent of GA efficacy varies according to disease-related variables at study entry. Three regression models were developed to assess the efficacy of GA on the annualized… CONTINUE READING